Apricus Biosciences, Inc.
04.08.2011 19:37
---------------------------------------------------------------------------
SAN DIEGO, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus
Bio' or the 'Company') (Nasdaq:APRI) (http://www.apricusbio.com) announced
today a corporate mid-year update covering Company activities, expected
near-term events and comments on recent market conditions, as follows:
Vitaros(r)
The key focus of the Company's management team has been, and continues to be,
partnering Vitaros(r), for the treatment of erectile dysfunction (ED), in
Canada,
Europe, and internationally; ramping up the manufacturing process for Vitaros(r)
for erectile dysfunction (ED), and; ensuring that Vitaros(r) launches in the
Canadian market by the end of this year.
Dr. Bassam Damaj, the Chairman, President and Chief Executive Officer of
Apricus Bio, noted, 'Our partnership negotiations for Vitaros(r) are proceeding
on a timely basis and we are confident that we will complete and announce our
partnership for Canada, and potentially for Europe, in the near future. As we
have stated previously, we are in multiple, late-stage partnership negotiations
with various pharmaceutical companies for a range of territories and
combinations. Our goal is to negotiate the most advantageous deal in each
territory, both in upfront financial terms and to ensure that each partner has
the capability to launch the product and achieve the sales and market
penetration that we believe is warranted. We believe that our shareholders will
be pleased, both in terms of the economics of our partnerships and the caliber
of our partners for these territories, once announced.'
He continued, 'We are also pushing, full-steam ahead with the scale up of
Vitaros(r) manufacturing. We have already completed our engineering batches, and
commercial batches are expected to be completed before the end of the year. In
parallel, the Company continues with its development of the room-temperature
formulation of Vitaros(r) for ED, as previously announced, and we have requested
guidance from Health Canada on the regulatory path required for approval.
'As stated earlier, we currently anticipate that Vitaros(r) will be introduced
in
Canada by the end of this year, though we may make it available online prior to
the launch, pending discussions with our partner. We believe that the market
will be pleased, both in terms of the economics of our partnerships and the
caliber of our partners for these territories, once announced.'
Femprox(r) and MycoVa(tm)
With regard to Femprox(r), for the treatment of female sexual arousal disorder
('FASD'), and MycoVa(tm), a topically-applied treatment for onychomycosis, or
nail
fungus, Dr. Damaj noted that the Company is continuing to work with its
Clinical Advisory Boards and health regulatory agencies with regard to guidance
on if, and when, the Company can file for marketing approvals in various
territories.
Specifically, the Company is currently moving forward with guidance from health
agencies in Europe and Canada in order to file for market authorization for
Femprox(r) in those markets. In the U.S., Apricus Bio intends to request a
meeting with the U.S. Food & Drug Administration (FDA) in order to come to
agreement on the second Phase III trial required before potential market
authorization.
'As for MycoVa(tm),' Dr. Damaj stated, 'despite the fact that the drug did not
show efficacy in a previously conducted Phase III trials in the general
onychomycosis patients population, the successful and statistically significant
reanalysis of our U.S. Phase III data has indicated that MycoVa(tm) is able,
over
an extended period of time, to kill the infecting fungus in 20% of patients
with mild to moderate dermatophyte onychomycosis (excluding patients with Tinea
Pedis, or athlete's foot) and is as effective as for the treatment of nail
fungus as the current European standard of care, Loceryl(r) (an ointment made by
Galderma) and Penlac(r) (an ointment made by Sanofi-aventis). As such, we plan
to
seek regulatory approval guidance in order to potentially market the product as
a treatment for nail fungus in Europe and North America. If successful, this
strategy may eliminate the time and costs to run an additional Phase III trial.
Moreover, if approved, MycoVa(tm) has the potential to represent the first
FDA-approved drug for which Apricus Bio would own the global rights.'
Finally, commenting on the macro environment, Dr. Damaj stated, 'The overall
market, and in particular, the small cap biotech sector, have been down
significantly. Despite this, we are proud of the progress that Apricus Bio has
made so far this year.'
Second Quarter 2011 Conference Call Information
The Company also announced today that it will be holding its second quarter
2011 teleconference call to discuss financial and operating results for the
three months ended June 30, 2011, at 4:00 pm ET on Monday, August 15, 2011 and
will provide further information closer to that date regarding dial-in
information.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiary, please visit www.nexmedusa.com. You can also
receive information at http://twitter.com/apricusbio and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop Vitaros(r),
Femprox(r) and MycoVa(tm) and other products and product candidates, to have its
products and product candidates approved by relevant European, U.S. and other
regulatory authorities, to successfully commercialize such products and product
candidates in Europe, the U.S. and other markets and to achieve its other
development, commercialization and financial goals. Readers are cautioned not
to place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's most
recent annual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are available
from the SEC's website or without charge from the Company.
Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
04.08.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences Provides Corporate Mid-Year Update
| Source: EQS Group AG